ZA200604721B - Naphthyridine derivatives and their use as modulators of muscarinic receptors - Google Patents
Naphthyridine derivatives and their use as modulators of muscarinic receptorsInfo
- Publication number
- ZA200604721B ZA200604721B ZA200604721A ZA200604721A ZA200604721B ZA 200604721 B ZA200604721 B ZA 200604721B ZA 200604721 A ZA200604721 A ZA 200604721A ZA 200604721 A ZA200604721 A ZA 200604721A ZA 200604721 B ZA200604721 B ZA 200604721B
- Authority
- ZA
- South Africa
- Prior art keywords
- modulators
- muscarinic receptors
- naphthyridine derivatives
- naphthyridine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52804903P | 2003-12-09 | 2003-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200604721B true ZA200604721B (en) | 2008-03-26 |
Family
ID=34676813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200604721A ZA200604721B (en) | 2003-12-09 | 2006-06-08 | Naphthyridine derivatives and their use as modulators of muscarinic receptors |
Country Status (13)
Country | Link |
---|---|
US (2) | US7446112B2 (fr) |
EP (1) | EP1709045A1 (fr) |
JP (1) | JP2007513955A (fr) |
KR (1) | KR20060123452A (fr) |
CN (1) | CN1914204A (fr) |
AU (1) | AU2004297241A1 (fr) |
CA (1) | CA2548009A1 (fr) |
IL (1) | IL176215A0 (fr) |
MX (1) | MXPA06006532A (fr) |
NO (1) | NO20063132L (fr) |
RU (1) | RU2006124559A (fr) |
WO (1) | WO2005056552A1 (fr) |
ZA (1) | ZA200604721B (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011217561B2 (en) * | 2010-02-22 | 2016-04-21 | Merck Patent Gmbh | Hetarylaminonaphthyridines |
US8507494B2 (en) | 2010-04-30 | 2013-08-13 | Merck Sharp & Dohme Corp. | Heterocyclic quinolizine derived M1 receptor positive allosteric modulators |
US8815902B2 (en) | 2010-06-15 | 2014-08-26 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide M1 receptor positive allosteric modulators |
EP2582241B1 (fr) | 2010-06-15 | 2016-04-06 | Merck Sharp & Dohme Corp. | Compposés de phénanthrolinone fusionnés hétérocycliques utiles comme modulateurs allostériques positifs du récepteur m1 |
WO2012003147A1 (fr) | 2010-07-01 | 2012-01-05 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs du récepteur m1 de l'isoindolone |
WO2012158473A1 (fr) | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs du récepteur m1 au n-méthyl tétrahydro-quinoline |
US8940765B2 (en) | 2011-05-17 | 2015-01-27 | Merck Sharp & Dohme Corp. | N-linked quinolineamide M1 receptor positive allosteric modulators |
EP2709451B1 (fr) | 2011-05-17 | 2015-12-30 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs du récepteur m1 contenant des lactames liés à n |
JP2016508487A (ja) * | 2013-01-28 | 2016-03-22 | ヴィアメット ファーマスーティカルズ,インコーポレイテッド | 金属酵素阻害剤化合物 |
CN107427506A (zh) | 2014-10-14 | 2017-12-01 | 拉霍拉敏感及免疫学研究所 | 低分子量蛋白酪氨酸磷酸酶的抑制剂及其用途 |
US10435403B2 (en) | 2015-06-09 | 2019-10-08 | Bayer Pharma Aktiengesellschaft | Positive allosteric modulators of muscarinic M2 receptor |
CN105646462B (zh) * | 2016-01-19 | 2019-04-05 | 河南大学 | 芸香宁碱衍生物、其制备方法及应用 |
WO2017160670A1 (fr) * | 2016-03-16 | 2017-09-21 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs du récepteur m1 et procédés pour les utiliser |
JP2019524722A (ja) | 2016-07-11 | 2019-09-05 | バイエル・ファルマ・アクティエンゲゼルシャフト | 7−置換1−ピリジル−ナフチリジン−3−カルボン酸アミドおよびその使用 |
JOP20190045A1 (ar) * | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
EP3296298A1 (fr) * | 2016-09-14 | 2018-03-21 | Bayer Pharma Aktiengesellschaft | 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation |
EA038451B1 (ru) * | 2016-12-06 | 2021-08-30 | Байер Акциенгезельшафт | 7-замещенные 1-арил-нафтиридин-3-амиды карбоновых кислот и их применение |
EP3619210A4 (fr) | 2017-05-01 | 2020-12-02 | Sanford Burnham Prebys Medical Discovery Institute | Inhibiteurs de la protéine tyrosine phosphatase de faible poids moléculaire (lmptp) et utilisations associées |
US9855255B1 (en) | 2017-05-26 | 2018-01-02 | King Saud University | Substituted naphthyridinyl hydrazines as anti-liver cancer agents |
IL301739A (en) | 2020-10-05 | 2023-05-01 | Enliven Therapeutics Inc | 5- and 6-Azaindole compounds for inhibition of BCR-ABL tyrosine kinases |
IL302807A (en) | 2020-11-18 | 2023-07-01 | Deciphera Pharmaceuticals Llc | GCN2 and PERK kinase inhibitors and methods of using them |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6166203A (en) * | 1998-02-26 | 2000-12-26 | Neurogen Corporation | Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands |
WO1999043681A1 (fr) * | 1998-02-26 | 1999-09-02 | Neurogen Corporation | Pyridines heteroaryle fondues substituees 4-(4-piperidylmethylamino); ligands du recepteur cerebral gaba |
GB9822450D0 (en) * | 1998-10-14 | 1998-12-09 | Smithkline Beecham Plc | Medicaments |
AU2910600A (en) * | 1999-02-12 | 2000-08-29 | Smithkline Beecham Plc | Phenyl urea and phenyl thiourea derivatives |
US6613776B2 (en) * | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
CA2422367C (fr) * | 2000-09-15 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Composes de pyrazole pouvant etre utilises comme inhibiteurs de la proteine kinase |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6610677B2 (en) * | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
KR100947185B1 (ko) * | 2000-12-21 | 2010-03-15 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물 |
ITMI20012060A1 (it) * | 2001-10-05 | 2003-04-05 | Recordati Chem Pharm | Nuovi eterocilcli n-acilati |
US7153889B2 (en) * | 2002-11-12 | 2006-12-26 | Abbott Laboratories | Bicyclic-substituted amines as histamine-3 receptor ligands |
-
2004
- 2004-12-07 EP EP04817977A patent/EP1709045A1/fr not_active Withdrawn
- 2004-12-07 WO PCT/US2004/040839 patent/WO2005056552A1/fr active Application Filing
- 2004-12-07 CN CNA2004800412909A patent/CN1914204A/zh active Pending
- 2004-12-07 KR KR1020067013734A patent/KR20060123452A/ko not_active Application Discontinuation
- 2004-12-07 AU AU2004297241A patent/AU2004297241A1/en not_active Abandoned
- 2004-12-07 MX MXPA06006532A patent/MXPA06006532A/es unknown
- 2004-12-07 JP JP2006543920A patent/JP2007513955A/ja not_active Withdrawn
- 2004-12-07 US US11/005,944 patent/US7446112B2/en not_active Expired - Fee Related
- 2004-12-07 RU RU2006124559/04A patent/RU2006124559A/ru not_active Application Discontinuation
- 2004-12-07 CA CA002548009A patent/CA2548009A1/fr not_active Abandoned
-
2006
- 2006-06-08 ZA ZA200604721A patent/ZA200604721B/xx unknown
- 2006-06-08 IL IL176215A patent/IL176215A0/en unknown
- 2006-07-05 NO NO20063132A patent/NO20063132L/no not_active Application Discontinuation
-
2008
- 2008-06-26 US US12/215,367 patent/US20090042928A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2004297241A1 (en) | 2005-06-23 |
US20050171141A1 (en) | 2005-08-04 |
US7446112B2 (en) | 2008-11-04 |
RU2006124559A (ru) | 2008-01-20 |
MXPA06006532A (es) | 2006-08-23 |
IL176215A0 (en) | 2006-10-05 |
EP1709045A1 (fr) | 2006-10-11 |
JP2007513955A (ja) | 2007-05-31 |
CA2548009A1 (fr) | 2005-06-23 |
KR20060123452A (ko) | 2006-12-01 |
CN1914204A (zh) | 2007-02-14 |
US20090042928A1 (en) | 2009-02-12 |
WO2005056552A1 (fr) | 2005-06-23 |
NO20063132L (no) | 2006-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200604721B (en) | Naphthyridine derivatives and their use as modulators of muscarinic receptors | |
AP2439A (en) | 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | |
EP1663204A4 (fr) | Modulateurs c-kit et leurs procedes d'utilisation | |
IL174419A0 (en) | Phenyl-piperazine derivatives as modulators of muscarinic receptors | |
IL208249A0 (en) | Spirocyclic heterocyclic derivatives and methods of their use | |
IL179526A0 (en) | Modulators of muscarinic receptors | |
HK1097256A1 (en) | Pyrizdazine derivatives and their use as therapeutic agents | |
HK1103730A1 (en) | Pyrrolopyridine derivatives and their use as crth2antagonists | |
IL181388A0 (en) | Modulators of muscarinic receptors | |
EP1603567A4 (fr) | Derives de benzamide tetracyclique et leurs procedes d'utilisation | |
IL176574A0 (en) | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss | |
EP1773826A4 (fr) | Modulateurs de c-met et leur methode d'utilisation | |
EP1610774A4 (fr) | Modulateurs de tie-2 et procedes d'utilisation | |
EP1678168A4 (fr) | Modulateurs des p70s6 kinases et procede d'utilisation | |
EP1786264A4 (fr) | Compositions antiseptiques cationiques et leurs procedes d'utilisation | |
IL216734A0 (en) | Azaindole derivatives and pharmaceutical compositions containing the same | |
IL178414A0 (en) | Azaindole derivatives and pharmaceutical compositions containing the same | |
IL172894A0 (en) | Indol-6-sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | |
EP1611123B8 (fr) | Modulateurs de tie-2 et procedes d'utilisation | |
ZA200710966B (en) | 2-Amino-4-Phenylquinazoline derivatives and their use as HSP90 modulators | |
IL172891A0 (en) | Indol-5-yl-sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | |
EP1871761A4 (fr) | Derives spirocycliques heterocycliques et procedes d'utilisation | |
EP1625111A4 (fr) | Derives de thyronamine et analogues et des methodes d'utilisation de ces composes | |
IL177302A0 (en) | Tricyclic imidazopyridine derivatives and pharmaceutical compositions containing the same | |
ZA200705116B (en) | Modulators of muscarinic receptors |